Affordable Access

Access to the full text

The Lotus Valve System: an In-depth Review of the Technology

Authors
  • Seigerman, Matthew E.1
  • Nathan, Ashwin1
  • Anwaruddin, Saif1
  • 1 Hospital of the University of Pennsylvania, Philadelphia, PA, USA , Philadelphia (United States)
Type
Published Article
Journal
Current Cardiology Reports
Publisher
Springer-Verlag
Publication Date
Nov 25, 2019
Volume
21
Issue
12
Identifiers
DOI: 10.1007/s11886-019-1234-5
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose of ReviewInnovation for transcatheter aortic valve replacement (TAVR) has transformed a medically complex treatment into a standardized procedure. While Edwards SAPIEN and Medtronic CoreValve occupy the market for TAVR in the United States (US), additional valve systems are being developed. The Boston Scientific Lotus Valve system was recently FDA-approved and will represent the third valve in the US market. This evidence-based review will summarize advantages, disadvantages, and projected impact of this new TAVR system.Recent FindingsThe Lotus Valve system demonstrates superiority in terms of rates of paravalvular leak, with similar rates of mortality and disabling stroke. This benefit is at the expense of increased pacemaker implantation rates, though preliminary data from subsequent iterations of the Lotus Valve suggest decreasing rates over time.SummaryThere is much anticipation from ongoing trials utilizing the Lotus Edge system, which may perform best for those with pre-existing pacemakers or anatomy that increases likelihood of paravalvular leak.

Report this publication

Statistics

Seen <100 times